Suchergebnisse

The market expects Charles River Laboratories (CRL) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known

Charles River Laboratories International, Inc. CRL is scheduled to report second-quarter 2026 results on Aug. 5, before market open.

In the last reported quarter, the company’s adjusted earnings per

Charles River Laboratories (CRL) came out with quarterly earnings of $3.02 per share, beating the Zacks Consensus Estimate of $2.72 per share. This compares to earnings of $3.12 per share a year

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Charles River Laboratories (CRL) is a stock that can certainly grab the attention

For the quarter ended June 2026, Charles River Laboratories (CRL) reported revenue of $1 billion, down 2.7% over the same period last year. EPS came in at $3.02, compared to $3.12 in the year-ago

Charles River Laboratories International, Inc. CRL reported second-quarter 2026 company-defined non-GAAP earnings of $3.02 per share, down 3.2% year over year. The reported earnings topped the Zacks

Charles Schwab SCHW, one of the leading brokerage firms in the United States, has seen its stock rise almost 6% in a month. The company’s shares even hit an all-time high of $109.05 during

Charles River Associates CRAI reported second-quarter 2026 adjusted earnings of $2.16 per share, up 14.9% year over year, beating the Zacks Consensus Estimate of $2.12 by 1.9%. Revenues rose 12.8%